TypeSafe AI
Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.
$870MSeries A
ParticipantD
DCVC
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.
Recorded funding activity
TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 3 First participation on record · 1 follow-on
- Funding in participating rounds
- $1B 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionTypeSafe AI
Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.
$40MSeed
LeadShennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantCallosum
Software infrastructure allowing AI workloads to run across different chips and models
$100MSeed
Role not disclosed